Diversion ostomy improves treatment tolerance, conversion surgery, and survival compared with self-expanding metal stenting in initially unresectable obstructive colorectal cancer - Takeaways - MDSpire

Diversion ostomy improves treatment tolerance, conversion surgery, and survival compared with self-expanding metal stenting in initially unresectable obstructive colorectal cancer

  • By

  • Fengbin Cai

  • Weiming Jiang

  • Huali Cai

  • Bo Hu

  • July 15, 2026

Share

  • 1

    Diversion ostomy (DO) significantly improved the achievement of CROSS score 3 compared to self-expanding metal stenting (SEMS) in obstructive colorectal cancer patients.

  • 2

    Patients receiving DO had a higher median number of chemotherapy cycles (6) compared to those with SEMS (2), indicating better treatment tolerance.

  • 3

    The objective response and subsequent resection rates were significantly higher in the DO group (69.4%) compared to the SEMS group (30.2%).

  • 4

    Kaplan–Meier analysis showed that the median overall survival was significantly longer in the DO group (27.8 months) than in the SEMS group (10.3 months).

  • 5

    In multivariate analysis, SEMS was independently associated with worse overall survival compared to DO, with a hazard ratio of 2.231.

Original Source(s)

Diversion ostomy improves treatment tolerance, conversion surgery, and survival compared with self-expanding metal stenting in initially unresectable obstructive colorectal cancer

  • by Fengbin Cai, Weiming Jiang, Huali Cai, Bo Hu

  • July 15, 2026

Related Content

Medically Assisted Reproduction and Hormone-Related Cancers

Endoscopic mucosal resection versus endoscopic submucosal dissection for early colorectal cancer and precursor lesions: a retrospective study

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

  • by

  • July 7, 2026

  • 8 min